Core Viewpoint - A class action securities lawsuit has been filed against Fortinet, Inc. for alleged securities fraud affecting investors between November 8, 2024, and August 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Fortinet's management made false statements regarding the refresh cycle of their products, suggesting it would be more profitable than it actually was, as it involved old products that represented a "small percentage" of the Company's business [2]. - It is alleged that Fortinet misrepresented the number of FortiGate firewalls eligible for upgrades and that the refresh momentum was overstated, with approximately half of the refresh completed in just a few months by the end of Q2 2025 [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. due to alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding Telix's progress with prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects of the company [3]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role [4]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Primo Brands Corporation / Primo Water Corporation, alleging securities fraud that negatively impacted investors between June 17, 2024, and November 6, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed poor merger integration between Primo Water and BlueTriton Brands, citing technology and service issues as contributing factors [3]. - It is alleged that despite assurances of a "flawless" execution, Primo Brands faced significant supply disruptions that adversely affected customers and financial results [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 12, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - A class action securities lawsuit has been filed against Firefly Aerospace Inc. due to alleged securities fraud affecting investors who purchased shares during the company's IPO and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Firefly common stock during its IPO on August 7, 2025, and between August 7, 2025, and September 29, 2025 [2]. - The complaint alleges that Firefly overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program, which could have a material negative impact on the company [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until January 12, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5].

Core Viewpoint - The Freeport-McMoRan Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims related to safety issues at its Grasberg mine in Indonesia and subsequent operational impacts [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Reed v. Freeport-McMoRan Inc. and covers purchasers of Freeport-McMoRan securities from February 15, 2022, to September 24, 2025 [1]. - The lawsuit alleges that Freeport-McMoRan failed to ensure adequate safety at the Grasberg Block Cave mine, leading to heightened risks for workers [3]. - On September 9, 2025, Freeport-McMoRan reported a significant incident at the Grasberg mine, resulting in a nearly 6% drop in stock price [4]. - Following a tragic incident on September 24, 2025, where two team members were fatally injured, the company disclosed that production could be approximately 35% lower than pre-incident estimates for 2026, causing a nearly 17% decline in stock price [5]. Group 2: Regulatory and Reputational Risks - The lawsuit highlights that the lack of safety measures at the Grasberg mine constituted undisclosed regulatory, litigation, and reputational risks [3]. - An article published by Bloomberg on September 25, 2025, indicated that the halt in production at the Grasberg mine could strain relations with the Indonesian government, further impacting the company's stock, which fell more than 6% following the news [6]. Group 3: Legal Process and Representation - Investors who purchased Freeport-McMoRan securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of the class [7]. - Robbins Geller Rudman & Dowd LLP, a leading law firm in securities fraud litigation, is representing the investors in this case [8].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Allegations and Stock Performance - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, asserting that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6]. Executive Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO of James Hardie [7].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Freeport-McMoRan Inc. is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia, which manages the Grasberg Copper and Gold Mine [4]. Incident Details - On September 9, 2025, Freeport announced the suspension of mining operations at Grasberg due to a landslide, leading to a stock price drop of $2.77 per share, or over 5.9%, from $46.66 to $43.89 [6]. - Following an update on September 24, 2025, revealing two fatalities and five missing team members, the stock price fell by $7.69 per share, or nearly 17%, from $45.36 to $37.67 [7]. - On September 25, 2025, reports indicated that the incident strained Freeport's relationship with the Indonesian government, causing the stock to drop by $2.33 per share, or over 6%, from $37.67 to $35.34 [8]. - An Indonesian news report on September 28, 2025, suggested that the landslide was preventable, indicating that the risks associated with certain mining methods were known [9]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the District of Arizona, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][3]. Financial Performance and Stock Movement - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to certain long-lived assets, which was anticipated to be material. This announcement led to a significant stock price drop of approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [4]. - Following this, on November 3, 2025, the company delayed its earnings announcement for Q3 2025 due to the need for additional time to complete the impairment review, resulting in further declines in the stock price during trading on that day [5]. Company Operations and Asset Management - In late 2023, Beyond Meat conducted a global operations review and depreciated certain long-lived assets, stating that these assets were recorded at the lower of their carrying value or fair value less costs to sell, with no impairments reported [2].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [5][6]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price plummeted by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [8].